ILiAD Biotechnologies Reports First-ever Demonstration Of Protection Against B. pertussis Colonization In Phase 2b Human Challenge Study Of BPZE1 Vaccine
Portfolio Pulse from Happy Mohamed
ILiAD Biotechnologies has reported the first-ever demonstration of protection against B. pertussis colonization in a Phase 2b Human Challenge study of its BPZE1 vaccine. Network-1 Technologies, which has invested $7 million in ILiAD, announced the news. This investment represents approximately 6.8% of the outstanding units of ILiAD on a non-fully diluted basis.
September 06, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Network-1 Technologies, a stakeholder in ILiAD Biotechnologies, could see a positive impact due to the successful Phase 2b study of ILiAD's BPZE1 vaccine.
Network-1 Technologies has a significant stake in ILiAD Biotechnologies. The successful Phase 2b study of ILiAD's BPZE1 vaccine, which demonstrated protection against B. pertussis, could potentially increase the value of Network-1's investment, leading to a positive impact on its stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80